Express Scripts member plans have saved $230 million on cholesterol-fighting drugs through increased generic utilization since January 2006, the pharmacy benefit manager reports April 26. The PBM aggressively promoted therapeutic switching from Pfizer's Lipitor (atorvastatin) to Merck's Zocor (simvastatin) prior to the introduction of generic simvastatin (1"The Pink Sheet" Oct. 24, 2005, p. 19). With the launch of generic simvastatin and generic pravastatin (Bristol-Myers Squibb's Pravachol) in 2006, "use of generic cholesterol-fighting drugs has increased from eight percent to 44 percent," Express Scripts says...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.